Back to Results
First PageMeta Content
Medicine / Clinical medicine / Pyrimidines / Pyridines / Cancer / Stem cells / Piperazines / Chronic myeloid leukemia / Imatinib / Chronic myelogenous leukemia / Carlo Gambacorti-Passerini / Philadelphia chromosome


Articles and Brief Reports Chronic Myeloid Leukemia Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials
Add to Reading List

Document Date: 2012-10-16 11:38:35


Open Document

File Size: 1,76 MB

Share Result on Facebook